What the literature shows
The CJC-1295 research record: IGF-1 and where the evidence stops
Early human tests, laboratory animal studies, and a clear guide to what controlled trials never measured.
CJC-1295 review: what the published studies show
CJC-1295 entered scientific papers in 2005 [2]. Researchers tested a series of modified protein fragments (peptides). They sought a compound that resisted rapid breakdown. They wanted it to last in blood plasma. That is the liquid part of the blood. In animal tests, it remained detectable beyond 72 hours after injection [2]. It didn't clear rapidly.
Human tests followed in 2006 [1] [3]. Two clinical studies in healthy volunteers established the basic hormone responses. In 1 trial, a single injection produced a multi-day rise in growth hormone and liver-produced IGF-1. Your growth gland preserved its normal rhythmic pulses throughout that stimulation. A comprehensive 2024/2025 review compared CJC-1295 with sermorelin and tesamorelin [14]. Those are two related prescription drugs. Doctors already use them to stimulate growth hormone. The review explained how this long-lasting design works. Those early safety checks in healthy volunteers confirmed hormone changes in the blood. But clinical safety in healthy adults hasn't been proved. You can't treat it as proven medicine.
How CJC-1295 works inside your body
CJC-1295 attaches to growth hormone cell switches in your pituitary gland [1]. This stimulates your gland to produce and release natural growth hormone. It releases hormone in rhythmic pulses. That growth hormone travels to your liver. There, it prompts the release of IGF-1, a hormone that directs cells and tissues to grow.
The structure of the peptide — a small chain of protein pieces — determines how long it lasts in your system. Natural body messengers are broken down within minutes by blood enzymes [2]. Enzymes are specialized proteins that clear chemicals from circulation. Scientists modified the chain to shield it from these clearing enzymes [2]. In the DAC version, it forms a lasting bond with albumin. Albumin is a natural carrier protein in your bloodstream. That bond keeps the complex circulating. That's why 1 single shot keeps growth hormone elevated for days [1]. It won't disappear in minutes.
CJC-1295 findings: what early trials on IGF-1 measured
Discussions of CJC-1295 benefits focus on blood readings rather than everyday physical changes. In healthy volunteers, single shots of 30 micrograms for each kilogram of adult weight or 60 micrograms for each kilogram of adult weight lifted growth hormone [1]. They kept IGF-1 raised for 9 to 11 days. Repeated doses in 2 separate study groups kept IGF-1 elevated for up to 28 days. In healthy men, a single shot lifted hormone levels [3]. Researchers tested 60 micrograms for each kilogram of adult weight or 90 micrograms for each kilogram of adult weight. Average growth hormone levels climbed about 46%. Meanwhile, IGF-1 jumped about 45% after 1 week.
A laboratory trial in 11 healthy men confirmed that CJC-1295 raised specific blood carrier proteins [5]. Those proteins travel alongside liver-produced IGF-1. These measurable blood changes show that the compound acts on the hormone system. But they don't prove greater muscle mass, fat loss, or faster healing. No controlled trial of CJC-1295 has measured your body shape or physical strength [1] [3]. You won't find fitness proof in the papers.
What should you expect from CJC-1295?
Published human studies show a multi-day rise in growth hormone and liver-produced IGF-1 following a single skin shot [1] [3]. Wider claims about physical changes in healthy adults were never tested in clinical trials. These include more strength, muscle growth, or joint recovery. The medical literature measures short-term blood hormone changes. It stops there. It doesn't promise daily results for you.
What animal studies revealed
Animal tests in mice unable to make their own growth signal showed how CJC-1295 works over time. Given 2 micrograms once every 24 hours, CJC-1295 fully normalized body weight and growth [4]. Giving the shot every 48 or 72 hours was far less effective. That daily routine restored normal growth. It helped animals that couldn't produce their own messenger.
The early rat study [2] was foundational. Later trials used knockout mice — laboratory mice bred without the gene needed to make their own growth hormone [4]. Those tests proved that daily injections restored normal body growth in animals lacking the hormone. Both are animal studies. That means they measured growth in rodents rather than health outcomes in human patients. They don't prove human safety.
CJC-1295 compared with other growth messengers
As a synthetic growth messenger, CJC-1295 sits in a family that includes sermorelin and tesamorelin [14]. Tesamorelin is an approved prescription medicine used for excess belly fat in patients with HIV. Comparing them helps show how CJC-1295 was designed: it links to blood albumin so it lasts for days, unlike sermorelin which clears in minutes [2]. A 2025 medical review discussed this long-acting design across the growth hormone family [14]. A 2026 review on aging examined growth peptides in research settings without recommending them [15]. It didn't endorse daily use.
Forensic chemical testing forms another key part of public safety records. Testing is essential. Chemical analysis identified CJC-1295 inside unlicensed black-market vials [6]. Scientific papers on anti-doping describe methods used to detect it in sports drug testing [12] [13]. It's strictly banned in competition.
CJC-1295 side effects and reported health concerns
Side effects reported with CJC-1295 stem from sustained growth hormone and IGF-1 stimulation. Documented effects include water retention, swollen feet, and lower insulin sensitivity. That means cells struggle to absorb sugar, which can push blood sugar higher. Population surveys link chronically high IGF-1 to higher rates of certain tumors. That raises theoretical concerns if hormone levels remain high. Federal health reviews in 2024 warned about immune reactions to CJC-1295, such as red injection welts and severe allergic swelling.
Two important cautions come from the drug development history. An experimental Phase 2 clinical trial testing the compound for severe belly fat in HIV patients stopped after a volunteer died. That was a mid-stage test in patients with a specific condition. A direct causal link wasn't established in public records, but testing ended. These are documented safety cautions that anyone considering CJC-1295 should carefully weigh. You can't ignore these trial warnings.